NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ('Annovis') (NYSE:ANVS).
On July 28, 2021, after the market closed, Annovis reported clinical trial data for its Alzheimer's and Parkinson's disease drug Posiphen that failed to show statistical significance in treating patients relative to the placebo. Following this news, Annovis' stock price declined by $65.94 per share, over 60%.
Labaton Sucharow is investigating whether Annovis misled investors regarding the efficacy of Posiphen.
If you currently own stock or options of ANVS and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at firstname.lastname@example.org.
About the Firm
Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at labaton.com.
David J. Schwartz
SOURCE: Labaton Sucharow LLP
View source version on accesswire.com: